Citalopram
- Generic Name
- Citalopram
- Brand Names
- Celexa, Ctp
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21FN2O
- CAS Number
- 59729-33-8
- Unique Ingredient Identifier
- 0DHU5B8D6V
- Background
Citalopram is an antidepressant belonging to the class of selective serotonin-reuptake inhibitors (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs. Citalopram enhances serotonergic transmission through the i...
- Indication
Citalopram is approved by the FDA for treating adults with major depressive disorder. It has also been used off-label to treat various diseases, including but not limited to sexual dysfunction, ethanol abuse, psychiatric conditions such as obsessive-compulsive disorder (OCD), social anxiety disorder, panic disorder, and diabetic neuropathy.
- Associated Conditions
- Alcohol Abuse, Anorexia Nervosa (AN), Binge Eating Disorder (BED), Bulimia Nervosa, Depression, Diabetic Neuropathies, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Separation Anxiety Disorder, Social Anxiety Disorder (SAD)
- Associated Therapies
- -
Combination Treatment Study for Memory Impairment and Depression
- Conditions
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2017-10-17
- Lead Sponsor
- New York State Psychiatric Institute
- Target Recruit Count
- 86
- Registration Number
- NCT01658228
- Locations
- 🇺🇸
New York State Psychiatric Institute, New York, New York, United States
🇺🇸Duke University, Durham, North Carolina, United States
Citalopram Effects on Craving and Dopamine Receptor Availability in Alcoholics
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2019-07-23
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 31
- Registration Number
- NCT01657760
- Locations
- 🇺🇸
VA Greater Los Angeles Healthcare System, West Los Angeles, CA, West Los Angeles, California, United States
Unraveling the Nature of Impaired Pain Inhibition in Patients With Chronic Whiplash-associated Disorders
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2014-01-14
- Lead Sponsor
- Vrije Universiteit Brussel
- Target Recruit Count
- 59
- Registration Number
- NCT01601912
- Locations
- 🇧🇪
Universitair Ziekenhuis Brussel, Brussels, Belgium
Citalopram vs Clomipramine vs Placebo in Recurrent Depression
- Conditions
- Interventions
- First Posted Date
- 2012-04-11
- Last Posted Date
- 2012-04-11
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 59
- Registration Number
- NCT01575158
Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression
- First Posted Date
- 2012-03-20
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Mclean Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT01557946
- Locations
- 🇺🇸
McLean Hospital, Belmont, Massachusetts, United States
Citalopram for Cocaine Dependence
- First Posted Date
- 2012-02-17
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Joy Schmitz
- Target Recruit Count
- 108
- Registration Number
- NCT01535573
- Locations
- 🇺🇸
UT-Houston Behavioral and Biomedical Sciences Building, Houston, Texas, United States
Safety and Efficacy of Vilazodone in Major Depressive Disorder
- Conditions
- Interventions
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2014-08-08
- Lead Sponsor
- Forest Laboratories
- Target Recruit Count
- 1162
- Registration Number
- NCT01473381
- Locations
- 🇺🇸
Forest Investigative Site 034, Cromwell, Connecticut, United States
🇺🇸Forest Investigative Site 014, Allentown, Pennsylvania, United States
🇺🇸Forest Investigative Site 060, Atlanta, Georgia, United States
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
- Conditions
- Interventions
- First Posted Date
- 2011-09-20
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT01436643
- Locations
- 🇩🇪
Novartis Investigative Site, Zwickau, Germany
Emotional Processing in Healthy Volunteers in the Presence of an Investigational Anxiolytic
- Conditions
- Interventions
- First Posted Date
- 2011-08-29
- Last Posted Date
- 2017-07-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 54
- Registration Number
- NCT01424384
- Locations
- 🇬🇧
GSK Investigational Site, Oxford, United Kingdom
A Study of RO4995819 in Combination With Citalopram in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2011-06-07
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 32
- Registration Number
- NCT01367756
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.